Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

July 13, 2022 -Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

Leeds, UK and Toronto, CANADA – (July 13, 2022) MolecuLight Inc., the leader in fluorescence imaging for detection and localization of

Read More

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

June 29, 2022 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing

TORONTO, CANADA – (June 29, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion

Read More

MolecuLight Added to the ISWCAP 2022 Consensus Guidelines for Optimising Prevention of Surgical Wound Complications

June 1, 2022 -Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced

Read More

MolecuLight i:X® Receives Regulatory Clearance and Reimbursement in South Korea

April 6, 2022 -KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market

Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight

Read More

MolecuLight Featured in Unprecedented 32 Presentations and Posters at World Union of Wound Healing Societies (WUWHS) 2022 Conference

March 1, 2022 -Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care

Toronto, CANADA and Abu Dhabi, UNITED ARAB EMIRATES – (March 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces

Read More

Latest Clinical Evidence Presented at APWCA’s Wound Week™ 2022 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

February 24, 2022 -8 Clinical Posters and a Presentation and Hands-On Workshop Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications

Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads,

Read More